Reinhard Dummer, Marguerite Krasovec, J. Röger
Dec 1, 1993
Citations
1
Influential Citations
67
Citations
Quality indicators
Journal
Journal of the American Academy of Dermatology
Abstract
BACKGROUND Hexadecylphosphocholine is a new antineoplastic drug that inhibits tumor cell growth directly and, in addition, might have immunoregulatory properties. OBJECTIVES We investigated the topical application of this phospholipid in patients with cutaneous lymphoma. METHODS Twenty-four patients with histologically documented cutaneous lymphoma were treated for 8 weeks. Lesions that responded to treatment were biopsied and evaluated histologically. RESULTS Of 15 patients with cutaneous T-cell lymphomas, 12 were evaluable. Two complete remissions, four partial remissions, and one minor remission were observed. Of seven patients with B-cell lymphomas, six were evaluable. One complete remission, three partial remissions, one case of stable disease, and one case of progressive disease were seen. However, histologic monitoring demonstrated only a partial clearing of infiltrating lymphocytes in lesions that showed a partial or complete response clinically. Both patients with lymphomatoid papulosis had complete clearing of the lesions clinically. An objective response rate (partial and complete response) of 56% (10/18) was achieved in the patients with cutaneous lymphoma who were treated in this study. CONCLUSION Hexadecylphosphocholine appears to be effective topically in the treatment of some cases of cutaneous lymphomas.